Treatment of idiopathic sclerosing inflammation of the orbit (myositis) with infliximab.
OBJECTIVE
We report the successful use of infliximab in a young patient with idiopathic sclerosing orbital inflammation (myositis).


METHODS
We describe the patient's medical records and review the literature.


RESULTS
Idiopathic myositis in this patient could not be satisfactorily treated with corticosteroids or chemotherapy. Biopsy showed sclerosing orbital inflammation. The patient had a prompt and sustained response with infliximab and methotrexate treatment.


CONCLUSIONS
Infliximab and methotrexate might be considered in patients with idiopathic sclerosing orbital inflammation (myositis).
Sahlin
Sven
S
St Erik's Eye Hospital, Karolinska Institute, Stockholm, Sweden. sven.sahlin@sankterik.se
Lignell
Börje
B
Williams
Maria
M
Dastmalchi
Maryam
M
Orrego
Abiel
A
D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D000069285:Infliximab; D008279:Magnetic Resonance Imaging; D008727:Methotrexate / Q000627:therapeutic use*; D055622:Orbital Myositis / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology*; D019233:Retreatment; D012598:Sclerosis; D017211:Treatment Failure
D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D000069285:Infliximab; D008727:Methotrexate